Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Alimta Favorable Toxicity Outweighs Uncertain Survival Effect, Cmte Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s oncologic drugs advisory committee recommends accelerated approval of Alimta for the treatment of second line non-small cell lung cancer. Alimta results in less neutropenia and other adverse events, committee says.

You may also be interested in...



Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival

While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.

Lilly's Alimta Approved For Lung Cancer; "Reasonably Likely" To Improve Survival

While no controlled trials demonstrated a clinical benefit of pemetrexed in non-small cell lung cancer, a surrogate endpoint of patient response rate suggests a survival benefit.

Taxotere Would Be Unaffected By Alimta Approval, Aventis Says

Aventis expects Taxotere growth to remain unchanged should FDA approve Lilly's thymidylate synthase inhibitor Alimta for the treatment of second line non-small cell lung cancer

Related Content

Topics

UsernamePublicRestriction

Register

PS060140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel